Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix General Counsel Mary Ann Moore to exit by October 31, 2026; David Haddock named successor

Neutral Impact 3 of 5 leadership Written later

Pediatrix Medical Group said its General Counsel, Chief Administrative Officer and Secretary, Mary Ann E. Moore, will serve in an advisory role until October 31, 2026, when she leaves the company. The company also named David Haddock as Executive Vice President, General Counsel and Secretary, a senior legal role that shareholders may watch as the transition takes effect.

Key points

  • Mary Ann E. Moore's transition is a termination without cause under her employment agreement, with benefits specified in that agreement.
  • Moore will serve in an advisory role until October 31, 2026, under a Separation Agreement signed July 21, 2026.
  • David Haddock was appointed Executive Vice President, General Counsel and Secretary.
  • The company first reported the planned transition on May 1, 2026.

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECJul 24, 2026, 5:00 PM ET
Accession number0001193125-26-316225

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.